EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Long-term health-related quality of life and rhythm outcomes of catheter ablation versus antiarrhythmic drugs in patients with atrial fibrillation

Victoria Svedung Wettervik, Jonas Schwieler, Lennart Bergfeldt, Göran Kennebäck, Steen Jensen, Aigars Rubulis, Elena Sciaraffia, Carina Blomström-Lundqvist

Heart Rhythm · 2025-04 · 22 (4) · 944-951

DOI: 10.1016/j.hrthm.2024.09.044 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Heart Rhythm, 2025-04. Verfasst von Victoria Svedung Wettervik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: victoria.svedung.wettervik@medsci.uu.se. Hauptthemen laut MEDLINE: Atrial Fibrillation, Quality of Life, Anti-Arrhythmia Agents, Catheter Ablation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Medtronic, Heart and Lung Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Data on long-term effects of catheter ablation vs antiarrhythmic drugs (AADs) on health-related quality of life (HRQoL) and atrial fibrillation (AF) burden are limited. OBJECTIVE: The study aimed to assess long-term HRQoL and rhythm data in patients with symptomatic AF. METHODS: The 75 patients who underwent ablation and 74 receiving AADs in the Catheter Ablation compared with Pharmacological Therapy for Atrial Fibrillation (CAPTAF) trial were followed for 48 months. The General Health subscale of the 36-Item Short-Form Health Survey, time to first AF episode ≥1 hour, and AF burden, recorded by implantable cardiac monitors, were compared. RESULTS: One hundred forty-seven patients completed follow-up, with 7 crossovers in the ablation group and 34 crossovers in the AAD group. General Health improved by ablation from a median of 62 points at baseline to 79.2 points at follow-up (P < .001) and by AADfrom a median of 67 to 77 points (P < .001), without treatment differences (P = .77). Time to first AF episode ≥1 hour was longer (median 257 days in the ablation group vs 180 days in the AAD group; P = .025). The cumulative AF burden during follow-up was lower in the ablation group (median 0.3%; interquartile range [IQR] 0%-1.4%) than in the AAD group (1.6%; IQR 0.1%-11.0%); P = .01. The cumulative reduction in AF burden compared with baseline was greater in the ablation group (median -89.5%; IQR -98.4% to -51.3%) than in the AAD group (-52.7%; IQR -92.6% to 263.6%); P < .001. CONCLUSION: HRQoL improvement in long-term did not differ between ablation and AAD groups despite a larger reduction in AF burden after ablation. The results should be interpreted in the light of a high crossover rate in the AAD group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationQuality of LifeAnti-Arrhythmia AgentsCatheter AblationHeart RateHumansMaleFemaleMiddle AgedTreatment OutcomeFollow-Up StudiesAgedTime Factors

Stichwörter der Autor:innen

Antiarrhythmic drugsAtrial fibrillationCatheter ablationHealth-related quality of lifeImplantable cardiac monitors

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: victoria.svedung.wettervik@medsci.uu.se.
  • Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Region Västra Götaland, Department of Cardiology, Sahlgrenska University Hospital, Gothenburg,…
  • Heart Centre, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  • Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Department of Cardiology, School of Medical Science, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Förderung

  • Swedish Research Council
  • Medtronic
  • Heart and Lung Foundation

Zitieren

APA

Svedung Wettervik, V., Schwieler, J., Bergfeldt, L., Kennebäck, G., Jensen, S., Rubulis, A., Sciaraffia, E., & Blomström-Lundqvist, C. (2025). Long-term health-related quality of life and rhythm outcomes of catheter ablation versus antiarrhythmic drugs in patients with atrial fibrillation. Heart Rhythm, 22(4), 944-951. https://doi.org/10.1016/j.hrthm.2024.09.044

Vancouver

Svedung Wettervik V, Schwieler J, Bergfeldt L, Kennebäck G, Jensen S, Rubulis A, et al. Long-term health-related quality of life and rhythm outcomes of catheter ablation versus antiarrhythmic drugs in patients with atrial fibrillation. Heart Rhythm. 2025;22(4):944-951. doi:10.1016/j.hrthm.2024.09.044

BibTeX
@article{SvedungWettervik2025,
  author = {Svedung Wettervik, Victoria and Schwieler, Jonas and Bergfeldt, Lennart and Kennebäck, Göran and Jensen, Steen and Rubulis, Aigars and Sciaraffia, Elena and Blomström-Lundqvist, Carina},
  title = {Long-term health-related quality of life and rhythm outcomes of catheter ablation versus antiarrhythmic drugs in patients with atrial fibrillation},
  journal = {Heart Rhythm},
  year = {2025},
  volume = {22},
  number = {4},
  pages = {944--951},
  doi = {10.1016/j.hrthm.2024.09.044}
}
Kostenlos starten →